Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patientâ€™s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
26-06-23	A$0.7500	+0.67%	44,317
26-06-23	A$0.7450	-2.61%	344,329
26-06-22	A$0.7650	+4.08%	698,405
26-06-19	A$0.7350	-4.55%	482,123
26-06-18	A$0.7700	0.00%	174,321

Delayed Quote Australian S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7450AUD

Average target price

1.250AUD

Spread / Average Target

+67.79%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Australian S.E. Other stock markets 22:21:39 2026-06-23 EDT			5-day change	1st Jan Change
0.7500 ^AUD	+0.67%		-2.60%	-30.88%

04-30	Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada	MT
04-27	Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%	MT

Market Cap	203M 140M 123M 114M 106M 199M 13.31B 1.37B 529M 6.53B 527M 516M 22.7B	P/E 2026 *	-18.6x	P/E 2027 *	-37.3x
Enterprise Value	160M 111M 97.41M 89.76M 84.02M 157M 10.5B 1.08B 417M 5.15B 416M 407M 17.91B	EV / Sales 2026 *	12.8x	EV / Sales 2027 *	7.39x
Free-Float	83.36%	Yield 2026 *	-	Yield 2027 *	-

04-30	Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada	MT
04-27	Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%	MT
04-21	Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says	MT
04-20	Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%	MT
04-19	Orthocell says qtrly A$3.2 million revenue achieved	RE
04-16	Orthocell's first surgical use of Remplir in US Department of Defense	RE
04-16	Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed	MT
04-16	Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital Networks	CI
04-14	Orthocell Ltd receives approval for Remplir in 51 Department of Defense hospitals	RE
04-14	Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks	MT
04-07	Orthocell Says Proposed US Pharmaceutical Tariffs Not Expected to Apply to Remplir; Shares Up 4%	MT
04-07	Orthocell says US Section 232 tariffs not expected to affect Remplir	RE
03-18	Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target	MT

04-21	Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says	MT
03-18	Bell Potter Starts Orthocell at Speculative Buy with AU$1.15 Price Target	MT
12-17	Canaccord Genuity Starts Orthocell at Speculative Buy with AU$1.33 Price Target	MT
25-10-02	Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says	MT
25-04-08	Orthocell's Remplir FDA Clearance 'Major Milestone', Says Euroz Hartleys	MT

Orthocell Limited Stock

Stocks

OCC

AU000000OCC6

Advanced Medical Equipment & Technology

Valuation: Orthocell Limited

Chart: Orthocell Limited

Latest news : Orthocell Limited

Analysts' recommendations: Orthocell Limited

Press Releases: Orthocell Limited

News in other languages: Orthocell Limited

Quotes and Performance

Course Extremes

Managers and Directors: Orthocell Limited

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

24-05-15	Orthocell reports 98.6% success rate in Striate+â„¢ dental membrane study	AQ
24-02-23	Orthocell raising $3.5 million; adds heavy hitters to register	AQ
23-11-01	Orthocell on the cusp of significant growth	AQ
23-05-29	Orthocell thrilled to welcome John Van Der Wielen as chairman	AQ
23-03-30	Orthocell welcomes globally recognised nerve surgeons to advisory board	AQ

1 day	+0.67%
1 week	-2.60%
Current month	-1.96%
1 month	-6.25%
3 months	+3.45%
6 months	-31.82%
Current year	-30.88%

1 week	0.74	0.79
1 month	0.74	0.82
Current year	0.7	1.16
1 year	0.7	1.6
3 years	0.32	1.79
5 years	0.3	1.79
10 years	0.1	1.79

Manager	Title	Age	Since
Ming Hao Zheng CTO	Chief Tech/Sci/R&D Officer	-	2006-03-20
Paul Anderson CEO	Chief Executive Officer	60	2006-03-20
Jim Piper DFI	Director of Finance/CFO	-	2025-07-31

Director	Title	Age	Since
Paul Anderson BRD	Director/Board Member	60	2006-03-20
Ravi Thadhani BRD	Director/Board Member	60	2023-03-07
John van der Wielen CHM	Chairman	-	2023-05-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-02	Catrina Mcnulty	Buy		23,615	0.0087%
04-30	John van der Wielen	Buy	Chairman	25,000	0.0092%
02-24	John van der Wielen	Buy	Chairman	32,500	0.0120%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORTHOCELL LIMITED	+0.67%	-2.60%	-30.88%	+118.98%	146M
THERMO FISHER SCIENTIFIC, INC.	+1.15%	-0.69%	+17.28%	-10.47%	172B
INTUITIVE SURGICAL, INC.	+0.06%	-3.33%	-21.73%	+23.20%	143B
DANAHER CORPORATION	+0.44%	-1.31%	-8.85%	-24.86%	126B
BOSTON SCIENTIFIC CORPORATION	+2.86%	-2.81%	-55.45%	-15.51%	65.89B
EDWARDS LIFESCIENCES CORPORATION	+1.25%	-1.84%	+15.44%	-3.75%	49.45B
SIEMENS HEALTHINEERS AG	+0.06%	-2.21%	-25.84%	-32.63%	44.05B
AGILENT TECHNOLOGIES, INC.	+0.14%	-1.30%	+9.08%	+6.07%	35.72B
WATERS CORPORATION	-0.29%	-0.93%	+4.19%	+37.47%	35.18B
GE HEALTHCARE TECHNOLOGIES INC.	+5.08%	+0.77%	-10.46%	-20.17%	27.58B
Average	+0.73%	-1.82%	-10.72%	+7.83%	69.93B
Weighted average by Cap.	+0.54%	-1.98%	-7.27%	-4.69%

	2026 *	2027 *
Net sales	12.55M 8.69M 7.64M 7.04M 6.59M 12.34M 823M 84.49M 32.71M 404M 32.63M 31.93M 1.4B	23.55M 16.31M 14.33M 13.2M 12.36M 23.16M 1.55B 159M 61.37M 758M 61.24M 59.92M 2.64B
Net income	-12.5M -8.66M -7.61M -7.01M -6.56M -12.29M -820M -84.16M -32.58M -402M -32.5M -31.8M -1.4B	-7.85M -5.44M -4.78M -4.4M -4.12M -7.72M -515M -52.85M -20.46M -253M -20.41M -19.97M -878M
Net Debt	-42.75M -29.61M -26.01M -23.97M -22.44M -42.04M -2.81B -288M -111M -1.38B -111M -109M -4.78B	-28.75M -19.91M -17.49M -16.12M -15.09M -28.27M -1.89B -194M -74.93M -926M -74.76M -73.15M -3.22B